Enanta Pharmaceuticals, Inc. NASDAQ:ENTA

Enanta Pharmaceuticals stock price today

$8.39
+2.38
+39.6%
Financial Health
0
1
2
3
4
5
6
7
8
9

Enanta Pharmaceuticals stock price monthly change

-62.44%
month

Enanta Pharmaceuticals stock price quarterly change

-62.44%
quarter

Enanta Pharmaceuticals stock price yearly change

-37.72%
year

Enanta Pharmaceuticals key metrics

Market Cap
132.67M
Enterprise value
789.95M
P/E
-6.65
EV/Sales
9.62
EV/EBITDA
-6.64
Price/Sales
9.82
Price/Book
2.68
PEG ratio
0.13
EPS
-6.45
Revenue
72.67M
EBITDA
-134.62M
Income
-135.98M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-146.93%
Oper. margin
-150.37%
Gross margin
23.73%
EBIT margin
-150.37%
EBITDA margin
-185.25%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Enanta Pharmaceuticals stock price history

Enanta Pharmaceuticals stock forecast

Enanta Pharmaceuticals financial statements

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Profit margin
Mar 2023 17.79M -37.65M -211.62%
Jun 2023 18.89M -39.06M -206.78%
Sep 2023 18.93M -28.10M -148.46%
Mar 2024 17.05M -31.15M -182.7%
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Analyst Estimates
Sep 2023 18.93M -28.10M -148.46%
Mar 2024 17.05M -31.15M -182.7%
Sep 2025 14.85M -36.48M -245.62%
Oct 2025 16.42M -34.39M -209.4%
  • Analysts Price target

  • Financials & Ratios estimates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Earnings per share (EPS)
2023-05-08 -1.98 -1.63
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Debt to assets
Mar 2023 326445000 57.07M 17.48%
Jun 2023 495169000 257.35M 51.97%
Sep 2023 462275000 245.54M 53.12%
Mar 2024 413557000 247.44M 59.83%
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Cash Flow
Mar 2023 -13.78M 46.76M -2.02M
Jun 2023 -32.12M -145.74M 199.87M
Sep 2023 -21.60M 11.83M -23K
Mar 2024 -28.60M 58.62M -6.41M

Enanta Pharmaceuticals alternative data

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Employee count
Aug 2023 160
Sep 2023 160
Oct 2023 160
Nov 2023 160
Dec 2023 145
Jan 2024 145
Feb 2024 145
Mar 2024 145
Apr 2024 145
May 2024 145
Jun 2024 145
Jul 2024 145

Enanta Pharmaceuticals other data

36.93% -63.07%
of ENTA is owned by hedge funds
7.68M -11.44M
shares is hold by hedge funds

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Insider trades (number of shares)
Period Buy Sel
Jun 2024 0 7266
Jul 2024 0 11945
Dec 2024 0 15756
Transaction Date Insider Security Shares Price per share Total value Source
Sale
LUU BRENDAN officer: Chief Business Officer
Common Stock 2,283 $8.06 $18,401
Sale
KIEFFER TARA LYNN officer: Chief Product Strategy..
Common Stock 2,283 $8.06 $18,401
Sale
ROTTINGHAUS SCOTT T. officer: Chief Medical Officer
Common Stock 866 $8.06 $6,980
Sale
OR YAT SUN officer: Chief Sc.. Common Stock 2,591 $8.06 $20,883
Sale
MELLETT PAUL J officer: Chief Fi.. Common Stock 2,591 $8.06 $20,883
Sale
LULY JAY R. director, officer.. Common Stock 5,142 $8.06 $41,445
Option
ROTTINGHAUS SCOTT T. officer: Chief Medical Officer
Stock Option (Right to Buy) 5,375 $8.99 $48,321
Option
ROTTINGHAUS SCOTT T. officer: Chief Medical Officer
Common Stock 5,375 $8.99 $48,321
Sale
ROTTINGHAUS SCOTT T. officer: Chief Medical Officer
Common Stock 5,375 $17.08 $91,805
Sale
ROTTINGHAUS SCOTT T. officer: Chief Medical Officer
Common Stock 2,271 $15.04 $34,156
Patent
Grant
Filling date: 22 Jan 2021 Issue date: 23 Aug 2022
Application
Filling date: 13 Jan 2022 Issue date: 21 Jul 2022
Grant
Filling date: 27 Oct 2020 Issue date: 19 Jul 2022
Grant
Filling date: 20 Sep 2021 Issue date: 12 Jul 2022
Grant
Filling date: 29 Oct 2020 Issue date: 5 Jul 2022
Grant
Filling date: 9 Nov 2021 Issue date: 14 Jun 2022
Grant
Filling date: 20 Sep 2021 Issue date: 7 Jun 2022
Grant
Filling date: 19 Nov 2019 Issue date: 31 May 2022
Application
Filling date: 22 Nov 2021 Issue date: 26 May 2022
Application
Filling date: 20 Sep 2021 Issue date: 26 May 2022
Tuesday, 24 December 2024
businesswire.com
Monday, 23 December 2024
zacks.com
Monday, 9 December 2024
businesswire.com
Friday, 6 December 2024
businesswire.com
Monday, 25 November 2024
zacks.com
businesswire.com
Wednesday, 2 October 2024
zacks.com
Thursday, 26 September 2024
businesswire.com
Monday, 5 August 2024
zacks.com
businesswire.com
Monday, 15 July 2024
zacks.com
Wednesday, 29 May 2024
businesswire.com
Tuesday, 7 May 2024
businesswire.com
Monday, 6 May 2024
Seeking Alpha
Zacks Investment Research
Wednesday, 7 February 2024
Seeking Alpha
Zacks Investment Research
Wednesday, 31 January 2024
Business Wire
Friday, 5 January 2024
Zacks Investment Research
Tuesday, 19 December 2023
Zacks Investment Research
Monday, 27 November 2023
Zacks Investment Research
Monday, 20 November 2023
Seeking Alpha
Business Wire
Monday, 13 November 2023
Business Wire
Sunday, 17 September 2023
Business Wire
Monday, 7 August 2023
Seeking Alpha
Zacks Investment Research
Monday, 31 July 2023
Business Wire
Tuesday, 20 June 2023
Market Watch
Wednesday, 31 May 2023
Business Wire
  • What's the price of Enanta Pharmaceuticals stock today?

    One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $8.39.

  • When is Enanta Pharmaceuticals's next earnings date?

    Unfortunately, Enanta Pharmaceuticals's (ENTA) next earnings date is currently unknown.

  • Does Enanta Pharmaceuticals pay dividends?

    No, Enanta Pharmaceuticals does not pay dividends.

  • How much money does Enanta Pharmaceuticals make?

    Enanta Pharmaceuticals has a market capitalization of 132.67M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.61% to 67.64M US dollars. Enanta Pharmaceuticals made a loss 116.05M US dollars in net income (profit) last year or -$1.63 on an earnings per share basis.

  • What is Enanta Pharmaceuticals's stock symbol?

    Enanta Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ENTA".

  • What is Enanta Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Enanta Pharmaceuticals?

    Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Enanta Pharmaceuticals's key executives?

    Enanta Pharmaceuticals's management team includes the following people:

    • Dr. Jay R. Luly Pres, Chief Executive Officer & Director(age: 69, pay: $1,100,000)
    • Dr. Yat Sun Or Senior Vice President of R&D and Chief Scientific Officer(age: 73, pay: $675,480)
    • Dr. Nathalie Adda Senior Vice President & Chief Medical Officer(age: 59, pay: $644,090)
    • Mr. Nathaniel S. Gardiner J.D. Senior Vice President, Gen. Counsel & Sec.(age: 71, pay: $619,670)
    • Mr. Paul J. Mellett Jr. Senior Vice President of Fin. & Admin. and Chief Financial Officer(age: 70, pay: $612,520)
  • How many employees does Enanta Pharmaceuticals have?

    As Jul 2024, Enanta Pharmaceuticals employs 145 workers.

  • When Enanta Pharmaceuticals went public?

    Enanta Pharmaceuticals, Inc. is publicly traded company for more then 12 years since IPO on 21 Mar 2013.

  • What is Enanta Pharmaceuticals's official website?

    The official website for Enanta Pharmaceuticals is enanta.com.

  • Where are Enanta Pharmaceuticals's headquarters?

    Enanta Pharmaceuticals is headquartered at 500 Arsenal Street, Watertown, MA.

  • How can i contact Enanta Pharmaceuticals?

    Enanta Pharmaceuticals's mailing address is 500 Arsenal Street, Watertown, MA and company can be reached via phone at +61 76070800.

Enanta Pharmaceuticals company profile:

Enanta Pharmaceuticals, Inc.

enanta.com
Exchange:

NASDAQ

Full time employees:

145

Industry:

Biotechnology

Sector:

Healthcare

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

500 Arsenal Street
Watertown, MA 02472

CIK: 0001177648
ISIN: US29251M1062
CUSIP: 29251M106